DBV Technologies S.A Net Income 2015-2021 | DBVT

DBV Technologies S.A net income from 2015 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
DBV Technologies S.A Annual Net Income
(Millions of US $)
2020 $-160
2019 $-172
2018 $-196
2017 $-167
2016 $-127
2015 $-50
2014 $-32
2013 $-26
2012 $-17
DBV Technologies S.A Quarterly Net Income
(Millions of US $)
2021-09-30 $-24
2021-06-30 $-31
2021-03-31 $-29
2020-12-31 $-39
2020-09-30 $-31
2020-06-30
2020-03-31 $-41
2019-12-31
2019-06-30
2018-12-31
2018-06-30
2017-12-31
2017-06-30
2016-12-31
2015-12-31
2015-06-30
2014-12-31
2014-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.173B $0.011B
DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81